Experts discuss when to start therapy for pediatric low‑grade glioma, weighing chemo, MEK inhibitors and family factors

In a recent discussion, pediatric neuro‑oncologists examined how to decide when to begin treatment for low‑grade glioma in children. They highlighted the need to balance chemotherapy and MEK inhibitor options while considering vision loss, symptoms, tumor growth and the practical realities of each family.

The panel cautioned that the often‑cited 25% tumor growth threshold can be misleading, especially for small lesions where that amount of growth occurs quickly but may not affect the child’s health. Instead, they emphasized that observable changes in the patient’s functional status should drive the decision to treat.

Family dynamics also play a key role. Some families are hesitant to start therapy, preferring observation, while others feel more comfortable initiating treatment early to reduce anxiety. The experts stressed the importance of shared decision‑making tailored to each child’s situation.